The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection.

[1]  D. Brenner,et al.  Genomics of liver fibrosis and cirrhosis. , 2007, Seminars in liver disease.

[2]  F. Tacke,et al.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.

[3]  S. Friedman,et al.  Hepatic fibrosis 2006: Report of the third AASLD Single Topic Conference , 2007, Hepatology.

[4]  K. Lazaridis,et al.  Genomics and complex liver disease: Challenges and opportunities , 2006, Hepatology.

[5]  H. Tilg,et al.  How to modulate inflammatory cytokines in liver diseases , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[6]  P. Murphy,et al.  Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. , 2006, The American journal of pathology.

[7]  R. Vaughan,et al.  A CX3CR1 genotype associated with retinal vasculitis in patients in the United Kingdom. , 2006, Investigative ophthalmology & visual science.

[8]  Glen Kristiansen,et al.  Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue , 2006, International journal of cancer.

[9]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[10]  T. Liang,et al.  Hepatitis C — identifying patients with progressive liver injury , 2006, Hepatology.

[11]  S. Brand,et al.  Increased Expression of the Chemokine Fractalkine in Crohn's Disease and Association of the Fractalkine Receptor T280M Polymorphism with a Fibrostenosing Disease Phenotype , 2006, The American Journal of Gastroenterology.

[12]  T. Asselah,et al.  Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. , 2005, Gastroenterology.

[13]  C. Selmi,et al.  Polymorphism of the Fractalkine Receptor CX3CR1 and Systemic Sclerosis-associated Pulmonary Arterial Hypertension , 2005, Clinical & developmental immunology.

[14]  D. Thomas,et al.  Natural history of hepatitis C. , 2005, Clinics in liver disease.

[15]  C. Hellerbrand,et al.  Lack of association between the functional CX3CR1 polymorphism V249I and hepatocellular carcinoma , 2005 .

[16]  D. Brenner,et al.  Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282) , 2005 .

[17]  K. Isse,et al.  Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts , 2005, Hepatology.

[18]  T. Asselah,et al.  Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. , 2005, Virology.

[19]  S. Friedman,et al.  Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications , 2004, Nature Clinical Practice Gastroenterology &Hepatology.

[20]  L. Glimcher,et al.  Signaling pathways in Th2 development , 2004, Immunological reviews.

[21]  E. Chew,et al.  The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age‐related macular degeneration , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  T. Wynn.  Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[23]  F. Lammert,et al.  Haplotype‐tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C , 2004, Hepatology.

[24]  P. Donaldson.  Genetics of liver disease: immunogenetics and disease pathogenesis , 2004, Gut.

[25]  F. Lammert,et al.  From genotypes to haplotypes in hepatobiliary diseases: One plus one equals (sometimes) more than two , 2004, Hepatology.

[26]  A. Geerts.  On the origin of stellate cells: mesodermal, endodermal or neuro-ectodermal? , 2004, Journal of hepatology.

[27]  O. Yoshie,et al.  Fractalkine in Vascular Biology: From Basic Research to Clinical Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[28]  S. Szabo,et al.  Molecular mechanisms regulating Th1 immune responses. , 2003, Annual review of immunology.

[29]  Ramon Bataller,et al.  Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[30]  S. Milani,et al.  The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. , 2003, Gastroenterology.

[31]  A. Bosserhoff,et al.  A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. , 2003, Gastroenterology.

[32]  R. D'Agostino,et al.  Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. , 2003, The Journal of clinical investigation.

[33]  R. Hegele,et al.  Genomic Organization and Evolution of the CX3CR1/CCR8 Chemokine Receptor Locus* , 2003, The Journal of Biological Chemistry.

[34]  D. Schuppan,et al.  Hepatitis C and liver fibrosis , 2003, Cell Death and Differentiation.

[35]  S. Milani,et al.  Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. , 2002, Journal of hepatology.

[36]  P. Allavena,et al.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. , 2001, The Journal of clinical investigation.

[37]  T. Roskams,et al.  Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. , 2001, Journal of hepatology.

[38]  A. Gressner,et al.  Expression of isoforms and splice variants of the latent transforming growth factor beta binding protein (LTBP) in cultured human liver myofibroblasts. , 2001, Liver.

[39]  P. Debré,et al.  Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. , 2001, Blood.

[40]  E. Génin,et al.  Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. , 2000, Science.

[41]  D. Adams,et al.  Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. , 1999, Journal of immunology.

[42]  F. Marra,et al.  Monocyte chemotactic protein‐1 as a chemoattractant for human hepatic stellate cells , 1999, Hepatology.

[43]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[44]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[45]  P. Murphy.  The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.